Using exhaled nitric oxide (eNO) in treatment of adults and children with asthma produces positive results, according to research presented at the American Thoracic Society’s recent annual meeting.
“eNO measurement needs to be an integral part of asthma treatment, and we look forward to stronger studies and practice guidelines for eNO to bring this important marker into mainstream practice,” said Bhairavi Parikh, PhD, Apieron Founder and Chief Technology Officer. “In clinical practice, adopters of eNO monitoring have reported that eNO is predictive of asthma in patients with normal lung function, predictive of lack of compliance with proscribed therapy, and predictive of response to steroids.”
The Insight eNO System, employed in the study, has been available for use in the physician’s office since March 2008. Using a proprietary biosensor technology to measure exhaled nitric oxide, the system can help clinicians more closely manage their patients’ inflammatory condition and therefore more precisely titrate medications, which can lead to fewer exacerbations.
